# HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers

> **NIH NIH RM1** · YALE UNIVERSITY · 2022 · $163,596

## Abstract

Background & Significance: Chronic pain is a high prevalence problem for which full agonist opioids are
commonly prescribed. Harm of full agonist opioids may outweigh benefit in which case switch to buprenorphine
is often recommended. To make decisions about switching from full agonists to buprenorphine, patients and
providers need valid information about benefits and harms. The FDA recently issued a warning about the use
of transmucosal buprenorphine and dental problems based on an accumulated case series of approximately
315 cases without control patients. Therefore, there is a significant gap in understanding of the relative risk of
dental problems between full agonist opioids and buprenorphine
Innovation & Impact: Our study will harness the “Full VA” sample of the Veterans Aging Cohort Study (VACS)
containing ~8 million individuals to assess the relative risk of transmucosal buprenorphine vs. full opioid
agonists vs. no opioid therapy for dental problems using a rigorous cohort design, adjusting for hypothesized
confounders. This innovative work will examine various patterns of opioid exposure (full agonist vs. switch to
partial agonist) that reflect real-world clinical comparisons to inform risk discussions with patients.
Specific Aims: 1. To determine the association between incident long-term opioid agonist (full and partial)
receipt and tooth decay, cavities, oral infections, and loss of teeth (here forward referred to as composite
adverse dental outcome: CADO) compared to no long-term opioid agonist receipt, adjusting for relevant
sociodemographic and clinical factors. 2. Among individuals with incident long-term full agonist opioid receipt,
to examine the association between patterns (stay on full opioid agonists vs. switch to buprenorphine vs. stop)
of opioid receipt and CADO. 3. Among individuals with incident long term opioid receipt who do not switch, to
examine the association between greater opioid exposure (mg MEDD x time = total mg MEDD) and CADO,
stratified by immunosuppressive properties of individual opioids.
Methodology: Based on our previous methods using VA's Corporate Data Warehouse (CDW), we will identify
a large retrospective cohort of all Veterans with incident long-term opioid therapy (LTOT) over the period of
2010-2019, matched 1:2 with Veterans who lack LTOT receipt and observe the cohort over time for patterns of
opioid receipt—both full and partial agonist--and adverse dental outcomes. For the primary outcome (CADO), a
Cox proportional hazards model will be our primary approach to assessing pattern of opioid receipt,
demographic and treatment characteristics in relation to time to outcome. In the subset of patients who receive
full agonist opioids exclusively (i.e. lack partial agonist receipt), we will examine the association between total
quantity of opioid exposure, immunosuppressive properties of the opioids and adverse dental outcomes.
Next Steps/Implementation: Results of this study will help inform risk dis...

## Key facts

- **NIH application ID:** 10652027
- **Project number:** 3RM1DA055310-01S1
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** WILLIAM C BECKER
- **Activity code:** RM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $163,596
- **Award type:** 3
- **Project period:** 2021-09-30 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10652027

## Citation

> US National Institutes of Health, RePORTER application 10652027, HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (3RM1DA055310-01S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10652027. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*